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Introduction
Very few medicaments have 
been described in Ayurveda specially 
indicated for their usage in children. 
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Abstract
Balachaturbhadra Churna offers a multitude of health benefits for which it has become so 
poapular prescription by Kaumarbhritya practioners of Ayurveda. It is a combination of four 
drugs Musta, Pippali, Ativisha and Karkatashringi. This combination was first mentioned in 
Chakradatta and has been in practice since a millennium. Many queries have been raised 
on the usage of Aconite species of drugs recently, thus doubting the safety and efficacy of 
Balachaturbhadra Churna. Very few works have been published on Balachaturbhadra Churna 
till now. The aim of the present study was to compile and review such available references from 
classics and research works published on Balachaturbhadra Churna. Total five studies are 
published on Balachaturbhadra Churna, which revalidated the impact of classical guidelines. 
The research papers revealed standards of Quality Control and pharmacological efficacy of 
the drug. All the experimental studies revealed that Balachaturbhadra Churna is having no 
toxic hazards at very higher Dose levels, proving it safe for therapeutic use. Though certain 
limitations were observed in these researches, the results can be considered as a lead for 
further well stratified clinical studies.
Keywords: Balachaturbhadra Churna, pharmacology, Quality Control, standards, therapeutic 
use
One among them is Balachaturbhadra 
Churna (BCBC) which is a very 
popular and a  beneficial compound 
formulation in pediatric usage. It is a 
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widely practiced formulation that is 
indicated in respiratory disorders, fever, 
diarrhoea and vomiting of children 
(Joshi, et.al., 2013). 
The nomenclature of Ayurveda was 
primarily designed to help a physician 
select a plant for medicinal purposes. 
This is divided into three sub-topics 
named Nama (name), Rupa (form) and 
Yukti jnana (therapeutic usage), which 
constitutes the three-tier understanding 
of ausadhi (drug materials) 
(Viswanathan et.al., 2013). Bala means 
a child, Chatuhu means combination 
of four, and Bhadra means which is 
beneficial or best (Radhakantadeva, 
1961). Thus the term Balachaturbhadra 
denotes a combination of four drugs that 
are meant for use in children. The prefix 
Bala suggests that the combination is 
specially indicated in children and is 
potent enough to cure the diseases of the 
pediatric age group. 
India has a rich heritage of 
traditional herbal medicines. With the 
emerging interest of the world to adopt 
and study traditional systems, many 
opportunities have opened up to take 
advantage of the potential based on 
different healthcare systems (WHO, 
2000). The Ayurvedic pharmaceutical 
preparations evolved gradually from a 
simpler form to more complex forms 
based on plants and plant mineral 
combinations. This is the unique feature 
of herbal treatments, that one plant 
species can cure a particular disease and 
also can cure a number of other ailments 
in combination with other plant species. 
The clinical effect also varies with 
different dosages, forms and modes of 
administration. 
Very few research have been 
published on Balachaturbhadra 
Churna. Ativisha (Aconitum 
heterophyllum Wall.), one of the 
ingredients in this combination has 
been questioned by modern research 
industry for its safety. Aconite species 
are reported for its cardiotoxic as well 
as neurotoxic effects (Chan, 2009) 
but no studies related to the toxic 
effect of Aconitum heterophyllum 
Linn. in particular have been reported. 
Nonetheless the use of this formulation 
since millennia without reports of any 
untoward effect itself is a testimony to 
its safety. Still, an evaluation based on 
objective controlled experiments and a 
standardization of various parameters 
will provide proof for the undoubted 
usefulness of the drug.  In this article an 
attempt has been made to compile and 
critically evaluate the ancient classics 
and recent research publication of the 
drug Balachaturbhadra Churna.
Materials and Methods
Reviews of all references available 
for Balachaturbhadra Churna in 
classical texts as well as very recent 
literature were explored. Thorough 
searches were carried out on internet 
sources while articles published 
on Balachaturbhadra Churna in 
various journals were analyzed for 
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comprehensive understanding of the 
formulation.
Observations
The observations made from the 
review are mentioned under various 
headings as follows.
1. Classical references of BCBC
Balachaturbhadra Churna is 
mentioned for the first time in the text 
Chakradatta (Chakradatta et.al., 1976). 
Later period the same reference is found 
in several text books. The detailed 
description of references available is 
shown in table 1.
All the texts have mentioned the 
same four ingredients. Table 2 shows 
the constituents of Balachaturbhadra 
Churna. It is a fine powder prepared 
by mixing equal proportions of Musta 
(Cyperus rotundus Linn) rhizome, 
Pippali (Piper longum Linn) fruit, 
Ativisha (Aconitum heterophyllum 
Wall.) root and Karkatashringi (Pistacia 
integerrima Stew.) gall. It is given in the 
treatment of various pediatric diseases 
like Jvara (fever), Atisara (diarrhoea), 
Svasa and Kasa (respiratory disorders) 
and Chardi (vomiting) (Chakradatta, 
1976, Sharma and Vijnana, 2001). 
2. Pharmaceutical standardization
Ajazuddin et.al. in 2012 carried 
out investigations to study the 
physicochemical, phytochemical 
and spectrophotometric analysis of 
formulation (Ajazuddin, 2012). The 
values of percentage loss on drying, 
angle of repose, Hausner ratio, Carr’s 
index of the lab formulation were 
calculated as 6.84 ± 0.224, 27.36, 
1.25 and 20 respectively. Total ash, 
acid insoluble ash and water soluble 
ash were found 8.148 ± 0.337, 
3.281 ± 0.286, and 45.602 ± 0.414 
respectively. Alcoholic and aqueous 
extracts of formulations and ingredients 
were prepared and evaluated for 
phytochemical analysis and the results 
of extractive values shows higher 
alcoholic extractive value (39.294 ± 
Sr. No. Name of text books Reference Time period
1 Cakradatta 64/22 11th century A.D.
2 Gadanigraha 11/93 12th century A.D.
3 Sharangadhar Samhita 6/16 13th century A.D.
4 Bhavaprakasha 71/151 16th century A.D.
5 Yogaratnakara 71/39 17th century A.D.
6 Bhaishajya Ratnaval 71/39 18th century A.D.
7 Bhaishajya Samhita 7/50 20th century A.D.
8 Bharat Bhaishajya Ratnakar 7/24 20th century A.D.
9 Bala Tantra 13/10 20th century A.D.
10 Ayurvedic formulary of India part 1/page 92 20th century A.D.
Table 1. References available for Balachaturbhadra Churna
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2.226) of formulation depict that alcohol 
is a better solvent for extraction. Three 
laboratory batches of formulation and 
Piper longum powder were estimated 
for their piperine content against 
standard piperine solution on double 
beam UV-Visible spectrophotometer at 
λ max 342.5 nm. 
Shahebaz et.al. in 2012 made 
an attempt to evaluate and compare 
market formulation with in-house 
sample of Balchaturbhadra Churna 
by performing physico-chemical 
screening, phytochemical screening, 
microscopic characterization and 
fluorescence analysis (Ghadiyali 
et.al., 2012). Respective physical 
parameters observed for standard and 
market preparation of Balchaturbhadra 
Churna were Bulk Density (gm/
ml.) 0.5882 and 0.434, Tap Density 
(gm/ml) 0.8 and 0.625, Carr’s Index 
26.47 and 30.43, Hausner’s Ratio 
1.36 and 1.43 and Angle of Repose 
32.32 and 34.43. Morphological 
study of Balachaturbhadra Churna 
showed fine consistency for standard 
formulations and very fine for market 
formulations; colour was brown for 
standard formulations and greyish 
brown for market formulation, while 
Sr. No. Name of text books Reference Time period
1 Cakradatta 64/22 11th century A.D.
2 Gadanigraha 11/93 12th century A.D.
3 Sharangadhar Samhita 6/16 13th century A.D.
4 Bhavaprakasha 71/151 16th century A.D.
Table 2. Constituents of Balachaturbhadra Churna
it had a pleasant odour and bitter taste 
for both the formulations. Quantitative 
Analysis of microscopic constituent of 
standard and market formulations of 
Balachaturbhadra Churna observed 
were 3.43 and 3.24 for Starch Grains, 
55.12 and 52.56 for Xylem vessels and 
it was 170.76 and 176.34 for fibres 
(length). Screening of phytoconstituents 
in standard and market formulations 
of Balachaturbhadra Churna showed 
presence of alkaloids, flavonoids, 
phenolics, carbohydrates, tannins, 
Sterols and triterpenoids whereas 
coumarins and saponins were absent.
Estimation of phytoconstituents 
in standard and market formulations 
of Balachaturbhadra Churna were 
respectively 0.107% and 0.096% for 
Flavonoids, 0.84% and 0.76% for Na+ 
ion salts, 0.62% and 0.38% for K+ ion 
salts,  2.91 % and 3.74 % for Tannins 
and for Crude fibre content it was 
15.5% and 13%. Fluorescence analysis 
was performed by observing the powder 
of the standard and market formulation 
of Balachaturbhadra Churna with 1N 
HCL, 1N H2SO4, 1N HNO3, aquous 
and alcoholic NaOH, Iodine solution, 
KOH and NH3 and the fluorescence in 
day light and in UV light was compared 
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Qualitative test for various functional 
groups revealed the presence of 
carbohydrates, steroids, cardiac 
glycosides, flavanoids, alkaloids and 
tannins in the formulations. Saponin 
was absent in Churna. On performing 
HPTLC, the chromatogram showed 17 
peaks with Rf values at 254nm; while 
at 366nm the chromatogram showed 
14 spots. Commonly seen Rf values at 
both 254nm and 366nm were 0.14, 0.18, 
0.23, 0.29, 0.34, 0.35, 0.47, 0.53, and 
0.58.
3. Toxicity study
Parmar Parag et.al., in 2011 
conducted studies on acute toxicity 
study on albino rats.  Acute toxicity 
study was carried out as per WHO 
guideline for acute toxicity test and 
modified as per experimental need 
(Anonymous, 1993). The rats were 
observed closely for behavioural 
changes, sign and symptoms of toxicity 
and mortality continuously for the first 
four hours and thereafter periodically 
up to 14 days. Balacaturbhadrika 
Churna did not produce any signs and 
symptoms of toxicity and mortality up 
to a dosage of 2000 mg/kg in rats. 
Nariya M. et.al., in 2011 published 
data related toxicological study of 
Balachaturbhadrika Churna. The 
study was carried out by administering 
Balacaturbhadrika Churna in a dose 
up to 2000 mg/kg orally once. For 
long-term toxicity, Balacaturbhadrika 
Churna was administered in doses 
of 450 and 900 mg/kg orally for 
for both the samples. After analysis 
it was observed that market samples 
matched exactly with that of authentic 
standards of in-house formulation after 
performing the standardization. 
Abhishek Joshi et.al. in 
2013 made an attempt to develop 
Pharmacognostical, Pharmaceutical and 
HPTLC standards for Balachaturbhadra 
Churna. Organoleptic characters 
observed for Balachaturbhadra Churna 
were light brown colour, spicy pungent 
odour, Kashaya - Tikta (astringent – 
bitter) taste and fine consistency of the 
powder. Powder microscopy shows 
striking characters of all 4 individual 
constituents. Starch grains without 
hilum, dark brown colouring matter, 
annular vessels and lignified fibres of 
Musta, starch grains without hilum, 
stone cells and oil globules form 
Pippali, simple and compound starch 
grains, cork cells, prismatic crystals of 
calcium oxalate and parenchyma cells 
from Ativisha, tannin content material, 
fragments of pitted vessels, vascular 
bundles along with tannin cells and 
epidermal cells from Karkatashringi. 
Loss on drying, ash value, 
water soluble extract %w/w, alcohol 
soluble extracts %w/w, pH value 
of Balachaturbhadra Churna were 
4.7%w/w, 5.75%w/w, 29.3%w/w, 
27.3%w/w and 6 respectively. Particle 
size of Churna was ranging from 60- 
120 mesh. 3.209g, 2.345g, 1.360g, and 
3.019g was obtained from >60, 61-85, 
86-120 and >120 mesh respectively. 
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antibody formation and relative weight 
of spleen and the thymus of albino rats 
(Parmar, et.al., 2011). For cell mediated 
immunity Balacaturbhadrika Churna 
at dose of 100 mg/kg and 200 mg/
kg produced statistically significant 
changes on comparison with control 
group at 24 and 48 hours. Thus it can 
be inferred that the test drug produces 
significant suppression of cell mediated 
immunity. 
Balacaturbhadrika Churna did not 
affect antibody formation against Sheep 
RBC at significant level. Examination 
of spleen and thymus sections under 
microscope showed increase in features 
of increased cellularity. Though 
increased cellularity of thymus and 
spleen along with increased proportion 
of white pulp was observed, it does not 
seem to indicate immune stimulation 
rather it may be the tissue response to 
the CMI suppression observed with the 
test drug.
5. Clinical studies conducted to assess 
its efficacy
No study has been published till 
now to assess the clinical efficacy 
Balachaturbhadra Churna.
Discussion
An overview of the classics of 
Ayurveda throws light into the specific 
features of a child, which make them a 
subject for special considerations. The 
descriptions given in different contexts 
include Dosha Dushya Malalpata 
(quantitative and qualitative wise less 
45 consecutive days. The effects 
of the drug on ponderal changes, 
hematological, biochemical and 
histological parameters were noted.
The acute toxicity experiment 
showed that the drug did not produce 
any signs and symptoms of toxicity (or 
mortality) up to the dose of 2000 mg/
kg. This dose is more than 20 times 
the therapeutic equivalent dose in rats, 
clearly indicating that the formulation 
is unlikely to induce any drastic toxic 
effects. Long-term toxicity results 
showed that, even at higher dose of 900 
mg/kg, Balacaturbhadrika churna did 
not affect the parameters studied to a 
significant extent. 
The effect of Balacaturbhadrika 
Churna was studied on bone marrow 
cellularity. The test drug did not 
affect the polychromatic normoblasts, 
erythrocytes and normoblast showing 
micronuclei at both the dose levels 
studied, in comparison to the control 
group. This suggests that it is not likely 
to have any mutagenicity potential. The 
histopathological studies of 16 organs 
showed that Balacaturbhadrika Churna 
at 450 g/kg increased the cellularity in 
the thymus and spleen. Other organs 
exhibited normal cytoarchitecture 
suggesting that the preparation is devoid 
of serious organ degenerative potential 
at this dose level.
4. Pharmacological study 
pertaining to its efficacy
Parmar Parag et.al. also conducted 
studies on cell mediated immunity, 
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commentator on Charaka Samhita 
as well as Sushruta Samhita, in text 
Chakradatta mentioned the combination 
Balachaturbhadra Churna for the first 
time (Chakradatta et.al, 1976). Later 
to him almost all the renowned texts 
of Ayurveda including two from the 
famous Laghutrayees have described 
Balachaturbhadra Churna in their texts. 
The term Balacaturbhadrika has been 
used for Balachaturbhadra Churna in 
Bhaishajya Ratnavali (Dasa, 1983). 
There is no controversy regarding 
the constituents of Balachaturbhadra 
Churna mentioned in all texts of 
Ayurveda. The combination of these 
four drugs is unchanged in all these 
texts indicating the therapeutic 
effectiveness of this particular 
combination in pediatric disorders. 
Total five works related to 
Balachaturbhadra Churna which are 
published till now, were compiled in 
this work. 
Organoleptic studies reveal fine 
consistency, brownish appearance and 
bitter taste of the Churna (powder). 
All the studies of Churna which were 
analysed for Pharmacognosy were 
found having characters of all individual 
constituents. Striking characters like 
lignified fibres of Musta, starch grains 
without hilum from Pippali, cork cells, 
parenchyma cells from Ativisha were 
observed in all samples.
Physical parameters like bulk 
density, tap density, Carr’s index, 
Hausner’s ratio and angle of repose 
Dosha, Dushya, Mala), Soukumaryata 
(delicate by nature), Alpakayata 
(lower body mass index compared 
to adults), Sarvannanupa Sevana 
(not consuming all types of food), 
Aparipakwa Dhatu (immature state of 
Dhatus), Asampurna Bala (inadequate 
immunity), Kleshasahishnutwa (unable 
to withstand hardships), Ahara Sankarat 
Aniyatagni (unstable status of Agni as 
not acclimatized with different states 
of food materials) and Asamatvagata 
Prana Dosha Dhatu Maloujasam 
(unstable functional and structural 
entities in children) (Samhita, et.al. 
2009, Vagbhata et.al., 2005, Agnivesha 
et.al., 2009, Vridhhajeevaka, et.al. 
2009).
 All these postulations give a 
clear idea about the Dehabala (body 
strength), Agnibala (strength of 
digestive fire) and Satwabala (mental 
status) of the pediatric age group. 
Moreover they provide an idea about 
the lowered immune status of the child 
that makes them more susceptible 
for repeated infections. Another aim 
behind these considerations is that 
the child cannot tolerate all forms of 
medicaments and many of the treatment 
procedures, so these aspects are to be 
well considered in the planning and 
implementation of treatment protocol. 
Balachaturbhadra Churna is one such 
formulation mentioned in classics 
specially meant for use in pediatric 
practice.
Chakrapani Dutta, the famous 
8A Critical Review on Balachaturbhadra Churna: An Effective Ayurveda Formulation for the Pediatric Age
showed better flow property of 
Balachaturbhadra Churna. The loss 
on drying of any sample is directly 
related to its moisture content. The 
less value of moisture content could 
prevent bacterial, fungal or yeast growth 
(African pharmacopoeia, 1986). The 
values obtained in all studies were 
in accordance to the API standards 
(Anonymous, 2008). The ash value 
indicates the presence of inorganic 
and salt materials in the sample. The 
values obtained for all samples of 
Balachaturbhadra Churna were as per 
API standards except for one study by 
Ajazuddin et al. where it was partially 
higher (Saraf, 2012). This may be due 
to various factors involved right from 
cultivation of drug till manufacture of 
final product.
All the studies show high water-
soluble and alcohol soluble extractive 
values. This indicates the amount of 
active constituent and the bioavailability 
of the plant, in given amount of plant 
material when extracted with respective 
solvents. The pH of Balachaturbhadra 
Churna was found acidic. Phyto-
chemical screening reveals the presence 
of carbohydrates, steroids, glycosides, 
flavanoids, alkaloids, phenols and 
tannins in the formulations. Saponins is 
absent in Churna.
The Balachaturbhadra Churna 
did not modify humoral antibody 
formation, relative weight of spleen 
and the thymus of albino rats to 
significant extent. Immunological 
odema represents cell mediated immune 
response hence it can be inferred that 
the Balachaturbhadra Churna produces 
significant suppression of cell mediated 
immunity which is direct correlation of 
delayed type hypersensitivity (DTH) 
response and do not influence humoral 
immune response. The observed effect 
may be the main mechanism for the 
efficacy of the drug in respiratory 
disorders (Parmar, et.al., 2011). The 
acute and chronic toxicity experiments 
showed that the drug did not produce 
any signs and symptoms of toxicity 
even at very high dosages, which clearly 
indicates that the formulation is unlikely 
to induce any drastic toxic effect in 
spite of containing Aconitum species 
which is known for cardio-toxic and 
neurotoxic potential. The study on the 
effect of Balachaturbhadra churna on 
bone marrow cellularity suggests that it 
is not likely to have any mutagenicity 
potential (Nariya, et.al., 2011).
Conclusion
No clinical study has been 
published so far on this classical 
Ayurveda formulation. The doses 
employed for these toxicity studies 
as mentioned in pharmacology study 
were several times higher than normal 
clinical doses of Balachaturbhadra 
Churna, hence the observed changes 
will probably not become apparent 
at therapeutic dose level. This 
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Balachaturbhadra Churna can be 
considered safe for clinical use.[]
undoubtedly solves the safety concerns 
related to the presence of Aconitum 
species drug in the formulation. Thus 
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